stockrow
Saturday 7 November 2026
Export OBX’s income statement to Excel — free account
Obsidian Therapeutics, Inc
14.02
4.42
+46.04%
Follow OBX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Mar ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 8 | 8 | 8 | 0.0% | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | — | (83) | (101) | — | +21.1% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | — | — | (83) | (101) | — | +21.1% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | — | (6.47) | (7.22) | — | +11.6% | ||||||
| Cash flow | — | — | — | — | — | — | — | — | (5.84) | (6.49) | 0.00 | +11.1% | ||||||
| Capex | — | — | — | — | — | — | — | — | (0.06) | (0.01) | 0.00 | (91.4%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (5.90) | (6.49) | 0.00 | +10.1% | ||||||
| Book value | — | — | — | — | — | — | — | — | (13.58) | (19.09) | (15.63) | +40.6% | ||||||
| Shares, m | — | — | — | — | — | — | — | — | 13 | 14 | — | +8.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (75) | (90) | — | +20.5% | |||||
| Capex | — | — | — | — | — | — | — | — | (1) | 0 | — | (90.6%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (76) | (90) | — | +19.4% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 157 | 66 | 49 | (57.8%) | |||||
| Net debt | — | — | — | — | — | — | — | — | (168) | (80) | (59) | (52.2%) | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | (174) | (266) | (276) | +52.5% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (73.90) | — | (73.9) pt | |||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | 45.68 | — | +45.7 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | 3 | — | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | 0.00 | — | — | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 2 Nov 2026
Obsidian Therapeutics, Inc vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| GERN Geron Corporation | $610.4M | — (loss-making) | — (loss-making) | +27.45% (above 0%: growing) | n/m | +176.13% (above 0%: growing) | 89.95% | 9.63% | Compare |
| DSGN Design Therapeutics, Inc. | $605.2M | — (loss-making) | — (loss-making) | — | n/m | −7.00% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| KURA Kura Oncology, Inc. | $604.9M | — (loss-making) | — (loss-making) | +36.54% (above 0%: growing) | n/m | −109.05% (below 0%: shrinking) | 98.84% | (349.77%) | Compare |
| AVBP ArriVent BioPharma, Inc. | $603.0M | — (loss-making) | — | — | n/m | −51.51% (below 0%: shrinking) | — | 0.00% | Compare |
| IMMX Immix Biopharma, Inc. | $596.9M | — (loss-making) | — | — | n/m | −116.22% (below 0%: shrinking) | — | 0.00% | Compare |
| OBX Obsidian Therapeutics, Inc | $593.0M | — | — | — | n/m | — | — | 0.00% | |
| OLMA Olema Pharmaceuticals, Inc. | $591.5M | — (loss-making) | — | — | n/m | −54.33% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| APMD Apnimed, Inc. | $589.5M | 0.8× | 4.6× | — | — | — | 89.98% | (96.89%) | Compare |
| NVCT Nuvectis Pharma, Inc. | $579.8M | — (loss-making) | — | — | n/m | −34.57% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $600.0M | — | — | — | — | −51.51% | 89.95% | 0.00% |
Obsidian Therapeutics, Inc (OBX) Latest News
No news at this impact. Lower the threshold for more.